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Oxidative damageThe aged dog naturally develops cognitive decline in many different domains (including learning and memory)
but also exhibits human-like individual variability in the aging process. The neurobiological basis for cognitive
dysfunction may be related to structural changes that reﬂect neurodegeneration. Molecular cascades that
contribute to degeneration in the aging dog brain include the progressive accumulation of beta-amyloid (Aβ)
in diffuse plaques and in the cerebral vasculature. In addition, neuronal dysfunction occurs as a consequence
of mitochondrial dysfunction and cumulative oxidative damage. In combination, the aged dog captures key
features of human aging, making them particularly useful for the development of preventive or therapeutic
interventions to improve aged brain function. These interventions can then be translated into human clinical
trials. This article is part of a Special Issue entitled: Animal Models of Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
In this review of the canine model of human aging and Alzheimer
disease (AD), several key features of dog brain aging will be discussed
including general aging characteristics, cognitive changes with age,
and neuropathology that are consistent with the human brain. The
dog model provides a complementary system in which to test
various theories of aging and to develop therapeutics when used in
combination with other models. However, the use of dogs in aging
studies provides some unique advantages, as dogs are easy to handle
andmay share a common environment (including diet) with humans.
Dogs also offer additional predictive validity when translating results
to human clinical trials, as they absorb pharmaceuticals with similar if
not identical pharmacokinetics. For example, due to similarities to
humans in terms of responsiveness, drug tolerance and metabolism,
the dog can be considered to be a useful model for chronic statin
treatment [1,2]. Further, an interesting new study suggests that in
the process of domestication in dogs, genes associated with digestion
have been selected that allow dogs to thrive on a diet rich in starch
unlike wolves and more similar to humans [3], suggesting similar
dietary absorption of nutrients.
The median lifespan of dogs varies as a function of breed, with
larger breeds typically having shorter lifespan than smaller breeds
[4–6]. In our laboratory, we primarily work with beagles that have a
median lifespan of 13.9 years and no signiﬁcant differences between
males and females [7]. Using a polynomial model, a young beagle
under 5 years is similar to humans under 40 years [6]. Middle agedl Models of Disease.
.
l rights reserved.beagles between 5 and 9 years are similar to humans between 40
and 60 years and beagles over 9 years are similar to humans over
66 years. Interestingly, cognitive and neurobiological changes are
observed in dogs beginning in middle age and become more pro-
nounced as they progress to old age, consistent with humans.
Further, dogs may also capture the phenotype of early AD neuropa-
thology [8].
AD is accompanied by progressive dementia and the accumulation
of senile plaques and neuroﬁbrillary tangles [9]. Plaques contain a
toxic peptide called beta-amyloid (Aβ), which is produced from the lon-
ger Aβ precursor protein (APP) by sequential proteolytic cleavage by
beta-secretase and gamma-secretase [10]. Aβ forms either extracellular
deposits or soluble assembly states (oligomers — see Section 4.1)
[11–13]. Neuroﬁbrillary tangles are composed of hyperphosphorylated
tau protein that ﬁlls the cytoplasm of neurons, leading to degeneration
[14]. As with most natural animal models of AD (with the exception of
goats, sheep and chimpanzees, [15–17]), dogs develop Aβ pathology
and some evidence for tau abnormalities but not full blown neuroﬁbril-
lary tangles.2. Cognition and aging
Cognitive aging in dogs has several key features including
domain-speciﬁc vulnerabilities and individual variability in the
extent of decline. Aged dogs show deﬁcits in complex learning tasks
including size concept learning [18,19], oddity discrimination learn-
ing [20,21], size discrimination learning [22,23], and spatial learning
[24]. Tasks sensitive to prefrontal cortex function, including reversal
learning and visuospatial working memory, also deteriorate with
age [22,23,25]. Further, egocentric spatial learning and reversal
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their own body orientation) are also age-sensitive [24]. Spatial
attention assessed using a landmark discrimination task originally de-
veloped in nonhuman primates is also vulnerable to aging [26,27].
Interestingly, on simple visual discrimination learning tasks and pro-
cedural learning measures, aged dogs perform as well as younger an-
imals [28], suggesting that a subset of cognitive functions remains
intact with age. Further, sensory deﬁcits are likely not a signiﬁcant
contributor to increased error scores.
Memory also declines with age in dogs. To test memory, an object
recognition task developed for nonhuman primates [29] and applied
in the canine model also reveals age-related deﬁcits in acquisition
[28]. These age-dependent cognitive deﬁcits are not linked to obvious
sensory deﬁcits or locomotor impairment [30]. Perhaps the most
useful age-sensitive task in dogs is a spatial memory task in which
dogs are required to recognize the location of a sample stimulus and
then respond to a different location during the test trial. Spatial
learning and memory are age-sensitive in dogs [31,32]. Interestingly,
deterioration in spatial ability occurs early in the aging process,
between 6 and 7 years of age in dogs [25]. Thus, cognitive decline in
aged dogs is domain-speciﬁc and involves memory and executive
function cortical systems.
Cognitive dysfunction is not an inevitable consequence of aging in
humans [33]; research has focused on the distinction between those
who retain function and those who show decline, including mild cog-
nitive impairment [34,35]. As with human cognitive aging, increased
individual variability in error scores in dogs is observed beginning in
middle age [36]. Individual variability is largest in old animals. Using
spatial learning and memory tasks, it is possible to distinguish three
groups of old dogs: (1) successful agers, (2) impaired dogs whose
scores fell 2 standard deviations above the mean of the young ani-
mals, and (3) severely impaired dogs who failed to learn the task
[37]. This clustering of aged dogs on the basis of cognitive ability is
consistent with cognitive aging in rats and non-human primates
[38–42] as well as in humans [43]. Individual variability with age in
dogs provides a powerful approach to establish links between cogni-
tive dysfunction and neurobiology. With this approach, animals with
and without cognitive impairments at equivalent ages can be com-
pared for differences in the extent of neuropathology.
Tasks used to assess cognition in dogs were developed such that
they were conceptually analogous to those used in nonhuman
primate aging research and to detect dementia in humans. Table 1Table 1
Cognitive domains assessed in dog aging and comparison with nonhuman primate tasks an
Cognitive domain Dog task Localization in dog brain
Learning Visual discrimination learning Medial temporal lobe/parietal lobeb
Reward and object approach
learning
Nigrostriatal and motor cortexb






Spatial delayed nonmatch to
sample acquisition
Dorsolateral prefrontal cortex [23]
spatial delayed nonmatch to
sample memory
Hippocampus [122]
Executive function Visual reversal learning Prefrontal cortex/medial temporal lob




Size concept learning Prefrontal cortex/medial temporal lobe
Visuospatial function Landmark discrimination Prefrontal cortex/parietal cortexb
Egocentric spatial learning Hippocampus/medial temporal lobeb
a Neuropsychological tasks for humans that assess function in similar cognitive domains
b Proposed localization — not conﬁrmed in lesion studies in dogs.shows a comparison of the many tasks that have been modiﬁed or
developed for use in aging canines.3. Neurodegenerative changes in aged dog brain
Several structural and molecular changes occur with age in the
dog brain and are linked to cognitive function. In vivo brain imaging
studies show that cortical atrophy [44] and ventricular widening
[44–46] are consistent features of canine brain aging. Further, MRI
studies suggest differential vulnerabilities of speciﬁc brain areas to
aging. For example, in aging dogs, the prefrontal cortex loses tissue
volume at an earlier age (approximately 8–11 years) than does the
hippocampus (after 11 years) [47]. The extent of cortical atrophy
is signiﬁcantly associated with cognition; animals with extensive
atrophy perform more poorly on tests of learning and memory [48],
similar to elderly humans with dementia [49,50]. Another similarity
that has been reported between human brain aging and the canine
is the spontaneous development of white matter hyperintensities
seen with T2 imaging particularly in the white matter adjacent to
the lateral ventricles [45]. Mechanistically this may be linked to
changes in the capillaries of the white matter that have been reported
to show a decrease in laminin immunoreactivity and iron deposits
within astrocytes and macrophages, all of which suggest blood–
brain barrier and white matter compromise [51].
White matter volume also declines with age in dogs and, interest-
ingly, appears to show a different pattern in males and females [52].
Diffusion tensor imaging studies to measure changes in white matter
function have not been assessed as a function of age in dogs but a
recent report suggests that this may be a very useful tool in future
studies [53,54]. Given that dogs show a loss of myelin with age,
with the frontal cortex being particularly vulnerable, this may be
critically involved with cognitive decline [55].
Atrophy may result from neuron loss or changes in neuronal
density, as reported in normal human brain aging [56,57], although
more extensive neuronal loss occurs in AD [58,59]. When neurons
were counted using unbiased stereological methods within individual
subﬁelds of the hippocampus of young (3.4 to 4.5 years) and old
(13.0 to 15.0 years) dogs, the aged dogs had signiﬁcantly (~30%)
fewer neurons in the hilus of the dentate gyrus [60]. The number of
neurons was correlated with cognitive function; dogs with higher
numbers of hippocampal neurons performed a visual discriminationd analogous tasks used in human neuropsychological testing.
Nonhuman primate tasks Examples of human
neuropsychological tasksa
Visual discrimination learning [112,113] Digit copy, rotary pursuit, face
discrimination [114], object
discrimination [115,116]
Food pickup task, ﬁne motor learning
[117,118]
Object recognition memory task [28] Delayed recognition and recall,
digit span [119]
Object recognition memory task [28]
Delayed response task [120, 121]
Delayed response task [120, 121]
e [123] Visual reversal learning [112,113] Card or object sorting tasks, set
shifting, response inhibition [124]b N/A
Spatial reversal [112]
b Hierarchical/relational learning [125]
Landmark discrimination [126] Visual construction, block design,
spatial learning [115,116]Spatial learning [112]
reproduced from [127].
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accounts for a small number of neurons in the hippocampus overall.
Reduced neurogenesis in the mature brain may also contribute to
age-associated cognitive decline, resulting in slower replacement of
dying neurons. In the hippocampus of beagles, a 90–95% decline in
neurogenesis was measured in aged dogs [61]. Further, the degree
of neurogenesis was correlated with cognitive function; animals
with fewer new neurons had higher error scores in measures of learn-
ing and memory, as well as poorer learning ability [61]. Similar reduc-
tions in neurogenesis in aged dogs have been reported in other
laboratories [62,63].
4. Neurodegenerative mechanisms in aged dog brain
Neuron loss and cortical atrophy in vulnerable brain regions of the
aged dog may be due to the accumulation of toxic proteins, including
Aβ or oxidatively modiﬁed lipids, proteins, or DNA/RNA. Additionally,
many up-or down-regulated pathways in canine brain aging could
also lead to neurodegeneration [64].
4.1. Aβ and aging in dogs
Canines and humans have Aβ-containing lesions with identical
amino acid sequence [65,66]. This observation ﬁrst stimulated inter-
est in the use of the dog to model human aging and disease [67]. Spe-
ciﬁc brain regions show differential accumulation of Aβ in the aging
dog brain, paralleling reports in the aged human brain [66,68–75].
When cortical regions are sampled for Aβ deposition, each region
shows a different age of Aβ onset [72]. Aβ deposition occurs earliest
in the prefrontal cortex of the dog and later in temporal and occipital
cortex, similar to previous reports in humans [75]. Canine plaques are
typically diffuse and thioﬂavin S-negative but can form into more
compact deposits [76] — thus, although the brain regions affected
by senile plaques are similar in dogs and humans, they appear to
mimic an earlier phase of Aβ deposition [8]. Importantly, the extent
of Aβ plaque deposition in the dog brain is linked to the severity of
cognitive deﬁcits [22,48,77,78] and also in the prefrontal cortex to
cortical atrophy observed by MRI [47].
Age and cognitive status can predict Aβ accumulation in discrete
brain structures. For example, dogs with prefrontal cortex-dependent
reversal learning deﬁcits show signiﬁcantly higher amounts of Aβ in
this brain region [22,79]. On the other hand, dogs that did poorly in a
size discrimination learning task show large amounts of Aβ deposition
in the entorhinal cortex [22]. Aβ can also bemeasured in the cerebrospi-
nal ﬂuid (CSF) of dogs. The ratio of Aβ42/40 in the CSF is a good
predictor of the extent of Aβ measured biochemically in the brain and
also declines linearly with age [80].
Aβ not only exists in ﬁbrillar or linear conformations, but can also
adopt other assembly states that make it particularly toxic to synaptic
and neuronal function. Speciﬁcally, Aβ oligomers are small soluble
forms of Aβ that interfere with synaptic function and cognition
[11,81]. Interestingly, Aβ oligomers can be detected in the CSF of
dogs, but are inversely related to the amount of total Aβ measured
biochemically in the brain, suggesting that oligomers are sequestered
into plaques [80].
A common type of pathology observed in both normal human
brain aging and particularly in AD is the presence of cerebral amyloid
angiopathy (CAA), which is characterized by the accumulation of Aβ
in the walls of cerebral vessels [82–84]. Vascular and perivascular
abnormalities and CAA pathology are frequently found in aged dogs
[68,69,85–92]. CAA may compromise the blood–brain barrier, impair
vascular function [93], and cause microhemorrhages [90,91,94]. The
distribution of CAA in dog brain is similar to humans, with particular
vulnerability in the occipital cortex [83]. Thus, aged dogs develop
cerebrovascular abnormalities that may contribute to cognitive
decline and are consistent with those reported in humans.4.2. Oxidative damage and mitochondrial dysfunction
Aging and the production of free radicals can lead to oxidative dam-
age to proteins, lipids, and nucleotides that, in turn,may cause neuronal
dysfunction and ultimately neuronal death. Normally, the activity of
endogenous antioxidants balances the production of free radicals. How-
ever, a number of these protectivemechanisms begin to fail with age. In
the aging dog, the brain accumulates carbonyl groups, a measure of ox-
idative damage to proteins [95,96]. Carbonyl groups are associatedwith
reduced endogenous antioxidant enzyme activity or protein levels, in-
cluding those of glutamine synthetase and superoxide dismutase
(SOD) [95,97–99]. In addition, increased oxidative damage to proteins
can be measured by the end products of lipid peroxidation (oxidative
damage to lipids), including 4-hydroxynonenal (4HNE) [48,99–101],
lipofuscin [48], lipofuscin-like pigments [100,101] or malondialdehyde
[95]. Additionally, oxidative damage to DNA or RNA may be increased
in aged dog brain [8,48]. Oxidative damage may also be associated
with behavioral decline in dogs. Increased oxidative end products in
aged companion dog brain are correlated with more severe behavioral
changes [48,96,101,102]. Similarly, in laboratory studies of aging bea-
gles, higher protein oxidative damage (3-nitrotyrosine) and lower en-
dogenous antioxidant capacity (SOD and glutathione-S-transferase
activities) are associated with poorer prefrontal-dependent and spatial
learning [98]. Mitochondria are a source of free radicals that damage
proteins, lipids and DNA/RNA [103]. In a study of aged beagles, isolated
mitochondria show increased reactive oxygen species production in
aged animals relative to young animals [104]. Thus, aged dogs exhibit
mitochondrial dysfunction and oxidative damage, consistent with
humans with age-related neurological dysfunction.5. Therapeutics
Aging dogs have been used to test a number of different therapeutics
that has also been tested in human clinical trials [8]. A diet rich in a
broad spectrum of antioxidants andmitochondrial co-factors improved
cognition [21,26,105] and reduced neuropathology in aging dogs over a
2.8 year period of time [98,106]. There was also strong evidence for
maintenance of function over the duration of this study. Behavioral en-
richment, which includes physical exercise, environmental enrichment,
social enrichment and cognitive training also leads to signiﬁcant cogni-
tive [21,26,105] and neurobiological [98,106–108] beneﬁts. Statins have
been associated with reduced risk of AD [109–111]. Statins reduce cho-
lesterol levels by inhibiting the enzyme, 3-hydroxy-3-methylglutaryl
coenzyme reductase (HMG-CoA) to reduce cholesterol production. Ro-
dent models may have limited utility when testing the effects of statins
on the aging process as rats andmice upregulate HMG-CoA to compen-
sate after statin administration [112]. Aging dogs treated with human
dose atorvastatin showed both evidence of improved and impaired
cognition with decreased BACE protein levels [113], increased haem
oxygenase-1, and reduced oxidative damage [3,45]. No effects were
observed on Aβ pathology, which was the original hypothesis given
data from transgenic mice. However, a vaccine against Aβ, initially
developed in transgenic mice [114], leads to maintenance of frontal
function in aging dogs after 2 years of treatment alongwith a reduction
in Aβ plaques [115]. However, there was no improvement in learning
and memory while being vaccinated, which was similar to reports in
human clinical trials [116,117]. Recent reports suggest that passive
vaccination with solanezumab in patients with AD also did not re-
port beneﬁts but rather a delay in progression observed as a mainte-
nance of function. These studies suggest that the dog is a useful and
complementary model system to transgenic mice to help develop
therapeutics or approaches that may slow or halt AD in clinical trials.
A more thorough discussion of possible therapeutics development
using the canine model has been provided in additional reviews
[8,118].
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The aged dog naturally develops decline in many different cogni-
tive domains and exhibits human-like individual variability in the
aging process. Some aged dogs develop signiﬁcant cognitive decline
more closely resembling persons with mild cognitive impairment.
The neurobiological basis for cognitive dysfunction may be related
to structural changes that reﬂect degeneration. Molecular cascades
that may contribute to neurodegeneration in the dog brain may
include the progressive accumulation of Aβ in diffuse plaques and
in the cerebral vasculature. In addition, neuronal dysfunction may
occur as a consequence of mitochondrial dysfunction and cumulative
oxidative damage (although other pathological processes have been
observed in the canine brain and this review provides a few examples
of these). Taken together, the aged dog may capture key features of
human aging, making them particularly useful for studies of thera-
peutics that can be translated into human clinical trials.
Acknowledgements
Funding provided by the NIH/NIA AG0031764. The author also
appreciates the comments from Dr. Amy Dowling during the prepara-
tion of this review and to Paula Thomason for the editing.
References
[1] A.W. Alberts, Lovastatin and simvastatin— inhibitors of HMG CoA reductase and
cholesterol biosynthesis, Cardiology 77 (1990) 14–21.
[2] R.J. Gerson, J.S. MacDonald, A.W. Alberts, D.J. Kornbrust, J.A. Majka, R.J. Stubbs, D.L.
Bokelman, Animal safety and toxicology of simvastatin and related hydroxy-
methylglutaryl-coenzyme A reductase inhibitors, Am. J. Med. 87 (1989) 28S–38S.
[3] E. Axelsson, A. Ratnakumar, M.L. Arendt, K. Maqbool, M.T. Webster, M. Perloski,
O. Liberg, J.M. Arnemo, A. Hedhammar, K. Lindblad-Toh, The genomic signature
of dog domestication reveals adaptation to a starch-rich diet, Nature 495 (2013)
360–364.
[4] K.A. Greer, S.C. Canterberry, K.E. Murphy, Statistical analysis regarding the
effects of height and weight on life span of the domestic dog, Res. Vet. Sci. 82
(2007) 208–214.
[5] F. Galis, I. Van der Sluijs, T.J. Van Dooren, J.A. Metz, M. Nussbaumer, Do large
dogs die young? J. Exp. Zool. B Mol. Dev. Evol. 308 (2007) 119–126.
[6] G.J. Patronek, D.J. Waters, L.T. Glickman, Comparative longevity of pet dogs and
humans: implications for gerontology research, J. Gerontol. A Biol. Sci. Med. Sci.
52 (1997) B171–B178.
[7] L.A. Lowseth, N.A. Gillett, R.F. Gerlach, B.A. Muggenburg, The effects of aging on
hematology and serum chemistry values in the beagle dog, Vet. Clin. Pathol. 19
(1990) 13–19.
[8] C.W. Cotman, E. Head, The canine (dog) model of human aging and disease:
dietary, environmental and immunotherapy approaches, J. Alzheimers Dis. 15
(2008) 685–707.
[9] S.S. Mirra, The CERAD neuropathology protocol and consensus recommendations
for the postmortem diagnosis of Alzheimer's disease: a commentary, Neurobiol.
Aging 18 (1997) S91–S94.
[10] D.J. Selkoe, Normal and abnormal biology of the beta-amyloid precursor protein,
Annu. Rev. Neurosci. 17 (1994) 489–517.
[11] D.M. Walsh, I. Klyubin, J.V. Fadeeva, M.J. Rowan, D.J. Selkoe, Amyloid-beta
oligomers: their production, toxicity and therapeutic inhibition, Biochem. Soc.
Trans. 30 (2002) 552–557.
[12] S. Lesne, M.T. Koh, L. Kotilinek, R. Kayed, C.G. Glabe, A. Yang, M. Gallagher, K.H.
Ashe, A speciﬁc amyloid-beta protein assembly in the brain impairs memory,
Nature 440 (2006) 352–357.
[13] C. Haass, D.J. Selkoe, Soluble protein oligomers in neurodegeneration: lessons
from the Alzheimer's amyloid beta-peptide, Nat. Rev. Mol. Cell Biol. 8 (2007)
101–112.
[14] K. Iqbal, I. Grundke-Iqbal, Alzheimer neuroﬁbrillary degeneration: signiﬁcance,
etiopathogenesis, therapeutics and prevention, J. Cell Mol. Med. 12 (2008)
38–55.
[15] H. Braak, E. Braak, M. Strothjohann, Abnormally phosphorylated tau protein
related to the formation of neuroﬁbrillary tangels and neuropil threads in the
cerebral cortex of sheep and goat, Neurosci. Lett. 171 (1994) 1–4.
[16] P.T. Nelson, S.G. Greenberg, C.B. Saper, Neuroﬁbrillary tangles in the cerebral
cortex of sheep, Neurosci. Lett. 170 (1994) 187–190.
[17] R.F. Rosen, A.S. Farberg, M. Gearing, J. Dooyema, P.M. Long, D.C. Anderson, J.
Davis-Turak, G. Coppola, D.H. Geschwind, J.F. Pare, T.Q. Duong, W.D. Hopkins,
T.M. Preuss, L.C. Walker, Tauopathy with paired helical ﬁlaments in an aged
chimpanzee, J. Comp. Neurol. 509 (2008) 259–270.
[18] P.D. Tapp, C. Siwak, E. Head, C.W. Cotman, H. Murphey, B.A. Muggenburg, C.
Ikeda-Douglas, N.W. Milgram, Concept abstraction in the aging dog: developmentof a protocol using successive discrimination and size concept tasks, Behav. Brain
Res. 153 (2004) 199–210.
[19] C.T. Siwak, P.D. Tapp, E. Head, S.C. Zicker, H.L. Murphey, B.A. Muggenburg, C.J.
Ikeda-Douglas, C.W. Cotman, N.W. Milgram, Chronic antioxidant and mitochon-
drial cofactor administration improves discrimination learning in aged but not
young dogs, Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 461–469.
[20] N.W. Milgram, S.C. Zicker, E. Head, B.A. Muggenburg, H. Murphey, C.
Ikeda-Douglas, C.W. Cotman, Dietary enrichment counteracts age-associated
cognitive dysfunction in canines, Neurobiol. Aging 23 (2002) 737–745.
[21] C.W. Cotman, E. Head, B.A. Muggenburg, S. Zicker, N.W. Milgram, Brain aging in
the canine: a diet enriched in antioxidants reduces cognitive dysfunction,
Neurobiol. Aging 23 (2002) 809–818.
[22] E. Head, H. Callahan, B.A. Muggenburg, C.W. Cotman, N.W. Milgram, Visual-
discrimination learning ability and beta-amyloid accumulation in the dog,
Neurobiol. Aging 19 (1998) 415–425.
[23] P.D. Tapp, C.T. Siwak, J. Estrada, B.A. Muggenburg, E. Head, C.W. Cotman, N.W.
Milgram, Size and reversal learning in the beagle dog as a measure of executive
function and inhibitory control in aging, Learn. Mem. 10 (2003) 64–73.
[24] L.A. Christie, C.M. Studzinski, J.A. Araujo, C.S. Leung, C.J. Ikeda-Douglas, E. Head,
C.W. Cotman, N.W. Milgram, A comparison of egocentric and allocentric
age-dependent spatial learning in the beagle dog, Prog. Neuropsychopharmacol.
Biol. Psychiatry 29 (2005) 361–369.
[25] C.M. Studzinski, L.A. Christie, J.A. Araujo, W.M. Burnham, E. Head, C.W. Cotman,
N.W. Milgram, Visuospatial function in the beagle dog: an early marker of
cognitive decline in a model of human aging and dementia, Neurobiol. Learn.
Mem. 86 (2006) 197–204.
[26] N.W. Milgram, E. Head, B.A. Muggenburg, D. Holowachuk, H. Murphey, J.
Estrada, C.J. Ikeda-Douglas, S.C. Zicker, C.W. Cotman, Landmark discrimination
learning in the dog: effects of age, an antioxidant fortiﬁed diet, and cognitive
strategy, Neurosci. Biobehav. Rev. 26 (2002) 679–695.
[27] N.W. Milgram, B. Adams, H. Callahan, E. Head, W. Mackay, C. Thirlwell, C.W. Cotman,
Landmark discrimination learning in the dog, Learn. Mem. 6 (1999) 54–61.
[28] N.W. Milgram, E. Head, E. Weiner, E. Thomas, Cognitive functions and aging in the
dog: acquisition of nonspatial visual tasks, Behav. Neurosci. 108 (1994) 57–68.
[29] M. Mishkin, J. Delacour, An analysis of short-term visual memory in the monkey,
J. Exp. Psychol. Anim. Behav. Proc. 1 (1975) 326–334.
[30] E. Head, H. Callahan, B.J. Cummings, C.W. Cotman, W.W. Ruehl, B.A. Muggenberg,
N.W. Milgram, Open ﬁeld activity and human interaction as a function of age and
breed in dogs, Physiol. Behav. 62 (1997) 963–971.
[31] E. Head, R. Mehta, J. Hartley, A.M. Kameka, B.J. Cummings, C.W. Cotman, W.W.
Ruehl, N.W. Milgram, Spatial learning and memory as a function of age in the
dog, Behav. Neurosci. 109 (1995) 851–858.
[32] A.D. Chan, P.M. Nippak, H. Murphey, C.J. Ikeda-Douglas, B. Muggenburg, E. Head,
C.W. Cotman, N.W. Milgram, Visuospatial impairments in aged canines (Canis
familiaris): the role of cognitive-behavioral ﬂexibility, Behav. Neurosci. 116 (2002)
443–454.
[33] M.S. Albert, H.H. Funkenstein, The effects of age: normal variation and its
relation to disease, in: A.K. Asburg, G.M. McKhanney, W.I. McDonald (Eds.),
Disorders of the Nervous System: Clinical Neurology, 2nd edition, Saunders
Inc., Philadelphia, 1992, pp. 598–611.
[34] R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E. Kokmen, E.G. Tangelos, Aging,
memory, and mild cognitive impairment, Int. Psychogeriatr. 9 (Suppl. 1) (1997)
65–69.
[35] R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, E. Kokmen, Mild
cognitive impairment: clinical characterization and outcome, Arch. Neurol. 56
(1999) 303–308.
[36] B. Adams, A. Chan, H. Callahan, N.W. Milgram, The canine as a model of human
cognitive aging: recent developments, Prog. Neuropsychopharmacol. Biol.
Psychiatry 24 (2000) 675–692.
[37] E. Head, N.W. Milgram, C.W. Cotman, Neurobiological models of aging in the dog
and other vertebrate species, in: P. Hof, C. Mobbs (Ed.), Functional Neurobiology
of Aging, Academic Press, San Diego, 2001, pp. 457–468.
[38] M.G. Baxter,M.Gallagher, Neurobiological substrates of behavioral decline:models
and data analytic strategies for individual differences in aging, Neurobiol. Aging
(1996) 491–495.
[39] A.L. Markowska, W.S. Stone, D.K. Ingram, J. Reynolds, P.E. Gold, L.H. Conti, M.J.
Pontecorvo, G.L. Wenk, D.S. Olton, Individual differences in aging: behavioral
and neurobiological correlates, Neurobiol. Aging 10 (1989) 31–43.
[40] P.R. Rapp, D.G. Amaral, Recognition memory deﬁcits in a subpopulation of aged
monkeys resemble the effects of medial temporal lobe damage, Neurobiol.
Aging 12 (1991) 481–486.
[41] P.R. Rapp, Neuropsychological analysis of learning andmemory in aged nonhuman
primates, Neurobiol. Aging 14 (1993) 627–629.
[42] P.R. Rapp, M.T. Kansky, J.A. Roberts, H. Eichenbaum, New directions for studying
cognitive decline in old monkeys, Semin. Neurosci. 6 (1994) 369–377.
[43] J.W. Rowe, R.L. Kahn, Human aging: usual and successful, Science 237 (1987)
143–149.
[44] M.-Y. Su, E. Head, W.M. Brooks, Z. Wang, B.A. Muggenberg, G.E. Adam, R.J.
Sutherland, C.W. Cotman, O. Nalcioglu, MR imaging of anatomic and vascular char-
acteristics in a caninemodel of human aging, Neurobiol. Aging 19 (1998) 479–485.
[45] T. Kimotsuki, T. Nagaoka, M. Yasuda, S. Tamahara, N. Matsuki, K. Ono, Changes of
magnetic resonance imaging on the brain in beagle dogs with aging, J. Vet. Med.
Sci. 67 (2005) 961–967.
[46] J. Gonzalez-Soriano, P. Marin Garcia, J. Contreras-Rodriguez, P. Martinez-Sainz,
E. Rodriguez-Veiga, Age-related changes in the ventricular system of the dog
brain, Ann. Anat. 183 (2001) 283–291.
1388 E. Head / Biochimica et Biophysica Acta 1832 (2013) 1384–1389[47] P.D. Tapp, C.T. Siwak, F.Q. Gao, J.Y. Chiou, S.E. Black, E. Head, B.A. Muggenburg, C.W.
Cotman, N.W. Milgram, M.Y. Su, Frontal lobe volume, function, and beta-amyloid
pathology in a canine model of aging, J. Neurosci. 24 (2004) 8205–8213.
[48] J.E. Roﬁna, A.M. van Ederen, M.J. Toussaint, M. Secreve, A. van der Spek, I. van der
Meer, F.J. Van Eerdenburg, E. Gruys, Cognitive disturbances in old dogs suffering
from the canine counterpart of Alzheimer's disease, Brain Res. 1069 (2006) 216–226.
[49] A.T. Du, N. Schuff, L.L. Chao, J. Kornak, F. Ezekiel, W.J. Jagust, J.H. Kramer, B.R.
Reed, B.L. Miller, D. Norman, H.C. Chui, M.W. Weiner, White matter lesions are
associated with cortical atrophy more than entorhinal and hippocampal
atrophy, Neurobiol. Aging 26 (2005) 553–559.
[50] F. Ezekiel, L. Chao, J. Kornak, A.T. Du, V. Cardenas, D. Truran, W. Jagust, H. Chui, B.
Miller, K. Yaffe, N. Schuff, M. Weiner, Comparisons between global and focal
brain atrophy rates in normal aging and Alzheimer disease: Boundary Shift
Integral versus tracing of the entorhinal cortex and hippocampus, Alzheimer
Dis. Assoc. Disord. 18 (2004) 196–201.
[51] T. Morita, Y. Mizutani, M. Sawada, A. Shimada, Immunohistochemical and
ultrastructural ﬁndings related to the blood–brain barrier in the blood vessels
of the cerebral white matter in aged dogs, J. Comp. Pathol. 133 (2005) 14–22.
[52] P.D. Tapp, K. Head, E. Head, N.W. Milgram, B.A. Muggenburg, M.Y. Su,
Application of an automated voxel-based morphometry technique to assess
regional gray and white matter brain atrophy in a canine model of aging,
NeuroImage 29 (2006) 234–244.
[53] O. Jacqmot, B. Van Thielen, Y. Fierens, M. Hammond, I. Willekens, P. Van
Schuerbeek, F. Verhelle, P. Goossens, F. De Ridder, J.P. Clarys, A. Vanbinst, J. De
Mey, Diffusion tensor imaging of white matter tracts in the dog brain, Anat.
Rec. 296 (2013) 340–349.
[54] Y.C. Wu, A.S. Field, I.D. Duncan, A.A. Samsonov, Y. Kondo, D. Tudorascu, A.L.
Alexander, High b-value and diffusion tensor imaging in a canine model of
dysmyelination and brain maturation, NeuroImage 58 (2011) 829–837.
[55] J.K. Chambers, K. Uchida, H. Nakayama, White matter myelin loss in the brains of
aged dogs, Exp. Gerontol. 47 (2012) 263–269.
[56] G. Simic, I. Kostovic, B. Winblad, N. Bogdanovic, Volume and number of neurons
of the human hippocampal formation in normal aging and Alzheimer's disease,
J. Comp. Neurol. 379 (1997) 482–494.
[57] M.J. West, Regionally speciﬁc loss of neurons in the aging human hippocampus,
Neurobiol. Aging 14 (1993) 287–293.
[58] M.J. West, C.H. Kawas, L.J. Martin, J.C. Troncoso, The CA1 region of the human
hippocampus is a hot spot in Alzheimer's disease, Ann. N. Y. Acad. Sci. 908
(2000) 255–259.
[59] M. Bobinski, J. Wegiel, M. Tarnawski, M. Bobinski, B. Reisberg, M.J. de Leon, D.C.
Miller, H.M. Wisniewski, Relationships between regional neuronal loss and
neuroﬁbrillary changes in the hippocampal formation and duration and severity
of Alzheimer disease, J. Neuropathol. Exp. Neurol. 56 (1997) 414–420.
[60] C.T. Siwak-Tapp, E. Head, B.A. Muggenburg, N.W. Milgram, C.W. Cotman, Region
speciﬁc neuron loss in the aged canine hippocampus is reduced by enrichment,
Neurobiol. Aging 29 (2008) 521–528.
[61] C.T. Siwak-Tapp, E. Head, B.A. Muggenburg, N.W. Milgram, C.W. Cotman,
Neurogenesis decreases with age in the canine hippocampus and correlates
with cognitive function, Neurobiol. Learn. Mem. 88 (2007) 249–259.
[62] I.K. Hwang, K.Y. Yoo, H. Li, J.H. Choi, Y.G. Kwon, Y. Ahn, I.S. Lee, M.H. Won,
Differences in doublecortin immunoreactivity and protein levels in the
hippocampal dentate gyrus between adult and aged dogs, Neurochem. Res. 32
(2007) 1604–1609.
[63] A. Pekcec, W. Baumgartner, J.P. Bankstahl, V.M. Stein, H. Potschka, Effect of aging
on neurogenesis in the canine brain, Aging Cell 7 (2008) 368–374.
[64] K.S. Swanson, B.M. Vester, C.J. Apanavicius, N.A. Kirby, L.B. Schook, Implications
of age and diet on canine cerebral cortex transcription, Neurobiol. Aging 30
(2009) 1314–1326.
[65] E.M. Johnstone, M.O. Chaney, F.H. Norris, R. Pascual, S.P. Little, Conservation of
the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear
and ﬁve other mammals by cross-species polymerase chain reaction analysis,
Brain Res. Mol. Brain Res. 10 (1991) 299–305.
[66] D.J. Selkoe, D.S. Bell, M.B. Podlisny, D.L. Price, L.C. Cork, Conservation of brain
amyloid proteins in aged mammals and humans with Alzheimer's disease,
Science 235 (1987) 873–877.
[67] H.M. Wisniewski, J. Wegiel, J. Morys, C. Bancher, Z. Soltysiak, K.S. Kim, Aged dogs:
an animal model to study beta-protein amyloidogenesis, in: P.R.K. Maurer, H.
Beckman (Eds.), Alzheimer's disease. Epidemiology, Neuropathology, Neurochem-
istry and Clinics, Springer-Verlag, New York, 1990, pp. 151–167.
[68] G. Giaccone, L. Verga, M. Finazzi, B. Pollo, F. Tagliavini, B. Frangione, O. Bugiani,
Cerebral preamyloid deposits and congophilic angiopathy in aged dogs,
Neurosci. Lett. 114 (1990) 178–183.
[69] T. Ishihara, T. Gondo, M. Takahashi, F. Uchino, S. Ikeda, D. Allsop, K. Imai,
Immunohistochemical and immunoelectron microscopial characterization of
cerebrovascular and senile plaque amyloid in aged dogs' brains, Brain Res. 548
(1991) 196–205.
[70] H.M. Wisniewski, A.B. Johnson, C.S. Raine, W.J. Kay, R.D. Terry, Senile plaques
and cerebral amyloidosis in aged dogs, Lab. Investig. 23 (1970) 287–296.
[71] H.M. Wisniewski, Wegiel, J., Morys, J., Bancher, C., Soltysiak, Z. and Kim, K.S.,
Aged dogs: an animal model to study beta-protein amyloidogenesis, in: P.R.K.
Maurer, H. Beckman (Eds.), Alzheimer's disease. Epidemiology, Neuropathology,
Neurochemistry and Clinics, Springer-Verlag, New York, 1990, pp. 151–167.
[72] E. Head, R. McCleary, F.F. Hahn, N.W. Milgram, C.W. Cotman, Region-speciﬁc age
at onset of beta-amyloid in dogs, Neurobiol. Aging 21 (2000) 89–96.
[73] H. Braak, E. Braak, Neuropathological stageing of Alzheimer-related changes,
Acta Neuropathol. 82 (1991) 239–259.[74] H. Braak, E. Braak, J. Bohl, Staging of Alzheimer-related cortical destruction, Rev.
Clin. Neurosci. 33 (1993) 403–408.
[75] D.R. Thal, U. Rub, M. Orantes, H. Braak, Phases of A beta-deposition in the human brain
and its relevance for the development of AD, Neurology 58 (2002) 1791–1800.
[76] B.J. Cummings, J.H. Su, C.W. Cotman, R. White, M.J. Russell, Beta-amyloid
accumulation in aged canine brain: a model of plaque formation in Alzheimer's
disease, Neurobiol. Aging 14 (1993) 547–560.
[77] M.-A. Colle, J.-J. Hauw, F. Crespeau, T. Uchiara, H. Akiyama, F. Checler, P. Pageat,
C. Duykaerts, Vascular and parenchymal Ab deposition in the aging dog:
correlation with behavior, Neurobiol. Aging 21 (2000) 695–704.
[78] B.J. Cummings, E. Head, A.J. Afagh, N.W. Milgram, C.W. Cotman, Beta-amyloid
accumulation correlates with cognitive dysfunction in the aged canine, Neurobiol.
Learn. Mem. 66 (1996) 11–23.
[79] B.J. Cummings, E. Head,W.W. Ruehl, N.W.Milgram, C.W. Cotman, Beta-amyloid ac-
cumulation correlates with cognitive dysfunction in the aged canine, Neurobiol.
Learn. Mem. 66 (1996) 11–23.
[80] E. Head, V. Pop, F. Sarsoza, R. Kayed, T.L. Beckett, C.M. Studzinski, J.L. Tomic, C.G.
Glabe, M.P. Murphy, Amyloid-beta peptide and oligomers in the brain and cere-
brospinal ﬂuid of aged canines, J. Alzheimers Dis. 20 (2010) 637–646.
[81] R. Kayed, E. Head, J.L. Thompson, T.M. McIntire, S.C. Milton, C.W. Cotman, C.G.
Glabe, Common structure of soluble amyloid oligomers implies common
mechanism of pathogenesis, Science 300 (2003) 486–489.
[82] J. Attems, Sporadic cerebral amyloid angiopathy: pathology, clinical implications,
and possible pathomechanisms, Acta Neuropathol. 110 (2005) 345–359.
[83] J. Attems, K.A. Jellinger, F. Lintner, Alzheimer's disease pathology inﬂuences
severity and topographical distribution of cerebral amyloid angiopathy, Acta
Neuropathol. 110 (2005) 222–231.
[84] M.C. Herzig, W.E. Van Nostrand, M. Jucker, Mechanism of cerebral beta-amyloid
angiopathy: murine and cellular models, Brain Pathol. 16 (2006) 40–54.
[85] A. Shimada, M. Kuwamura, T. Akawkura, T. Umemura, K. Takada, E. Ohama, C.
Itakura, Topographic relationship between senile plaques and cerebrovascular
amyloidosis in the brain of aged dogs, J. Vet. Med. Sci. 54 (1992) 137–144.
[86] K. Uchida, Y. Tani, K. Uetsuka, H. Nakayama, N. Goto, Immunohistochemical
studies on canine cerebral amyloid angiopathy and senile plaques, J. Vet. Med.
Sci. 54 (1992) 659–667.
[87] K. Uchida, H. Nakayama, S. Tateyama, N. Goto, Immunohistochemical analysis of
constituents of senile plaques and cerebro-vascular amyloid in aged dogs, J. Vet.
Med. Sci. 54 (1992) 1023–1029.
[88] K. Uchida, R. Okuda, R. Yamaguchi, S. Tateyama, H. Nakayama, N. Goto,
Double-labeling immunohistochemical studies on canine senile plaques and
cerebral amyloid angiopathy, J. Vet. Med. Sci. 55 (1993) 637–642.
[89] K. Uchida, K. Kuroki, T. Yoshino, R. Yamaguchi, S. Tateyama, Immunohistochemical
study of constituents other than beta-protein in canine senile plaques and cerebral
amyloid angiopathy, 93 (1997).
[90] K. Uchida, Y. Miyauchi, H. Nakayama, N. Goto, Amyloid angiopathy with cerebral
hemorrhage and senile plaque in aged dogs, Nippon. Juigaku. Zasshi. 52 (1990)
605–611.
[91] K. Uchida, H. Nakayama, N. Goto, Pathological studies on cerebral amyloid
angiopathy, senile plaques and amyloid deposition in visceral organs in aged
dogs, J. Vet. Med. Sci. 53 (1991) 1037–1042.
[92] T. Yoshino, K. Uchida, S. Tateyama, R. Yamaguchi, H. Nakayama, N. Goto, A
retrospective study of canine senile plaques and cerebral amyloid angiopathy,
Vet. Pathol. 33 (1996) 230–234.
[93] R. Prior, D. D'Urso, R. Frank, I. Prikulis, G. Pavlakovic, Loss of vessel wall viability
in cerebral amyloid angiopathy, NeuroReport 7 (1996) 562.
[94] R. Deane, B.V. Zlokovic, Role of the blood–brain barrier in the pathogenesis of
Alzheimer's disease, Curr. Alzheimer Res. 4 (2007) 191–197.
[95] E. Head, J. Liu, T.M. Hagen, B.A. Muggenburg, N.W. Milgram, B.N. Ames, C.W.
Cotman, Oxidative damage increases with age in a canine model of human
brain aging, J. Neurochem. 82 (2002) 375–381.
[96] A. Skoumalova, J. Roﬁna, Z. Schwippelova, E. Gruys, J. Wilhelm, The role of free
radicals in canine counterpart of senile dementia of the Alzheimer type, Exp.
Gerontol. 38 (2003) 711–719.
[97] W. Kiatipattanasakul, S. Nakamura, K. Kuroki, H. Nakayama, K. Doi, Immunohisto-
chemical detection of anti-oxidative stress enzymes in the dog brain, Neuropathology
17 (1997) 307–312.
[98] W.O. Opii, G. Joshi, E. Head, N.W. Milgram, B.A. Muggenburg, J.B. Klein, W.M.
Pierce, C.W. Cotman, D.A. Butterﬁeld, Proteomic identiﬁcation of brain proteins
in the canine model of human aging following a long-term treatment with
antioxidants and a program of behavioral enrichment: relevance to Alzheimer's
disease, Neurobiol. Aging 29 (2008) 51–70.
[99] I.K. Hwang, Y.S. Yoon, K.Y. Yoo, H. Li, J.H. Choi, D.W. Kim, S.S. Yi, J.K. Seong, I.S.
Lee, M.H. Won, Differences in lipid peroxidation and Cu, Zn-superoxide
dismutase in the hippocampal CA1 region between adult and aged dogs, J. Vet.
Med. Sci. 70 (2008) 273–277.
[100] N. Papaioannou, P.C.J. Tooten, A.M. van Ederen, J.R.E. Bohl, J. Roﬁna, T. Tsangaris,
E. Gruys, Immunohistochemical investigation of the brain of aged dogs. I.
Detection of neuroﬁbrillary tangles and of 4-hydroxynonenal protein, an oxida-
tive damage product, in senile plaques, Amyloid: J. Protein Folding Disord. 8
(2001) 11–21.
[101] J.E. Roﬁna, K. Singh, A. Skoumalova-Vesela, A.M. van Ederen, A.J. van Asten, J.
Wilhelm, E. Gruys, Histochemical accumulation of oxidative damage products
is associated with Alzheimer-like pathology in the canine, Amyloid 11 (2004)
90–100.
[102] E. Barone, G. Cenini, F. Di Domenico, S. Martin, R. Sultana, C. Mancuso, M.P.
Murphy, E. Head, D.A. Butterﬁeld, Long-term high-dose atorvastatin decreases
1389E. Head / Biochimica et Biophysica Acta 1832 (2013) 1384–1389brain oxidative and nitrosative stress in a preclinical model of Alzheimer dis-
ease: a novel mechanism of action, Pharmacol. Res. 63 (2011) 172–180.
[103] M.K. Shigenaga, T.M. Hagen, B.N. Ames, Oxidative damage and mitochondrial
decay in aging, Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 10771–10778.
[104] E. Head, V.N. Nukala, K.A. Fenoglio, B.A. Muggenburg, C.W. Cotman, P.G. Sullivan,
Effects of age, dietary, and behavioral enrichment on brain mitochondria in a ca-
nine model of human aging, Exp. Neurol. 220 (2009) 171–176.
[105] N.W. Milgram, E. Head, S.C. Zicker, C.J. Ikeda-Douglas, H. Murphey, B.
Muggenburg, C. Siwak, D. Tapp, C.W. Cotman, Learning ability in aged beagle
dogs is preserved by behavioral enrichment and dietary fortiﬁcation: a
two-year longitudinal study, Neurobiol. Aging 26 (2005) 77–90.
[106] V. Pop, E. Head,M.A. Hill, D. Gillen, N.C. Berchtold, B.A.Muggenburg, N.W.Milgram,
M.P. Murphy, C.W. Cotman, Synergistic effects of long-term antioxidant diet and
behavioral enrichment on beta-amyloid load and non-amyloidogenic processing
in aged canines, J. Neurosci. 30 (2010) 9831–9839.
[107] M. Fahnestock, M. Marchese, E. Head, V. Pop, B. Michalski, W.N. Milgram, C.W.
Cotman, BDNF increases with behavioral enrichment and an antioxidant diet
in the aged dog, Neurobiol. Aging 33 (2012) 546–554.
[108] C.T. Siwak-Tapp, E. Head, B.A. Muggenburg, N.W. Milgram, C.W. Cotman, Region
speciﬁc neuron loss in the aged canine hippocampus is reduced by enrichment,
Neurobiol. Aging 29 (2008) 39–50.
[109] C. Cramer, M.N. Haan, S. Galea, K.M. Langa, J.D. Kalbﬂeisch, Use of statins and
incidence of dementia and cognitive impairment without dementia in a cohort
study, Neurology 71 (2008) 344–350.
[110] B. Wolozin, W. Kellman, P. Ruosseau, G.G. Celesia, G. Siegel, Decreased
prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl
coenzyme A reductase inhibitors, Arch. Neurol. 57 (2000) 1439–1443.
[111] B. Wolozin, S.W. Wang, N.C. Li, A. Lee, T.A. Lee, L.E. Kazis, Simvastatin is associ-
ated with a reduced incidence of dementia and Parkinson's disease, BMC Med.
5 (2007) 20.
[112] K.M. Thelen, K.M. Rentsch, U. Gutteck, M. Heverin, M. Olin, U. Andersson, A. von
Eckardstein, I. Bjorkhem, D. Lutjohann, Brain cholesterol synthesis in mice is
affected by high dose of simvastatin but not of pravastatin, J. Pharmacol. Exp.
Ther. 316 (2006) 1146–1152.
[113] M.P. Murphy, J. Morales, T.L. Beckett, G. Astarita, D. Piomelli, A. Weidner, C.M.
Studzinski, A.L. Dowling, X. Wang, H. Levine III, R.J. Kryscio, Y. Lin, E. Barrett,
E. Head, Changes in cognition and amyloid-beta processing with long term
cholesterol reduction using atorvastatin in aged dogs, J. Alzheimers Dis. 22
(2010) 135–150.
[114] D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, J. Huang, K.
Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L.Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T.
Yednock, D. Games, P. Seubert, Immunization with amyloid-beta attenuates
Alzheimer-disease-like pathology in the PDAPPmouse, Nature 400 (1999) 173–177.
[115] E. Head, V. Pop, V. Vasilevko, M. Hill, T. Saing, F. Sarsoza, M. Nistor, L.A. Christie,
S. Milton, C. Glabe, E. Barrett, D. Cribbs, A two-year study with ﬁbrillar
beta-amyloid (Abeta) immunization in aged canines: effects on cognitive
function and brain Abeta, J. Neurosci. 28 (2008) 3555–3566.
[116] S. Gilman, M. Koller, R.S. Black, L. Jenkins, S.G. Grifﬁth, N.C. Fox, L. Eisner, L. Kirby, M.B.
Rovira, F. Forette, J.M. Orgogozo, Clinical effects of Abeta immunization (AN1792) in
patients with AD in an interrupted trial, Neurology 64 (2005) 1553–1562.
[117] C. Holmes, D. Boche, D. Wilkinson, G. Yadegarfar, V. Hopkins, A. Bayer, R.W.
Jones, R. Bullock, S. Love, J.W. Neal, E. Zotova, J.A. Nicoll, Long-term effects of
Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised,
placebo-controlled phase I trial, Lancet 372 (2008) 216–223.
[118] S.B.Martin, A.L. Dowling, E. Head, Therapeutic interventions targeting Beta amyloid
pathogenesis in an aging dog model, Curr. Neuropharmacol. 9 (2011) 651–661.
[119] Z.C. Lai, M.B. Moss, R.J. Killiany, D.L. Rosene, J.G. Herndon, Executive system dys-
function in the aged monkey: spatial and object reversal learning, Neurobiol.
Aging 16 (1995) 947–954.
[120] P.R. Rapp, Visual discrimination and reversal learning in the aged monkey
(Macaca mulatta), Behav. Neurosci. 104 (1990) 876–884.
[121] A. Cronin-Golomb, Color vision, object recognition, and spatial localization in
aging and Alzheimer's disease, in: P.R. Hof, C.V. Mobbs (Eds.), Functional Neuro-
biology of Aging, Academic Press, San Diego, 2001, pp. 517–529.
[122] I. Boutet, N.W.Milgram,M. Freedman, Cognitive decline and human (Homo sapiens)
aging: an investigation using a comparative neuropsychological approach, J. Comp.
Psychol. 121 (2007) 270–281.
[123] M. Freedman, M. Oscar-Berman, Spatial and visual learning deﬁcits in
Alzheimer's disease and Parkinson's disease, Brain Cognit. 11 (1989) 114–126.
[124] M.E. Emborg, S.Y. Ma, E.J. Mufson, A.I. Levey, M.D. Taylor, W.D. Brown, J.E.
Holden, J.H. Kordower, Age-related declines in nigral neuronal function corre-
late with motor impairments in rhesus monkeys, J. Comp. Neurol. 401 (1998)
253–265.
[125] J.H. Kordower, Y.T. Liu, S. Winn, D.F. Emerich, Encapsulated PC12 cell transplants
into hemiparkinsonian monkeys: a behavioral, neuroanatomical, and neuro-
chemical analysis, Cell Transplant. 4 (1995) 155–171.
[126] M.D. Lezak, D.B. Howieson, D.W. Loring, Neuropsychological Assessment, 4th ed.
Oxford University Press, New York, 2004.
[127] A.F.T. Arnsten, P.S. Goldman-Rakic, Alpha 2-adrenergic mechanisms in prefron-
tal cortex associated with cognitive decline in aged nonhuman primates, Science
230 (1985) 1273–1276.
